ICON PLC (ICLR)

Services-Commercial Physical & Biological Research · market cap $12.8B · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-28 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

ICON PLC (ICLR) is an Irish-headquartered multinational contract research organization (CRO) with approximately 41,900 employees and a market cap of ~$10.8B at ~$168.77/share. The company provides clinical trial execution and drug development services to pharma and biotech clients. An upcoming earnings catalyst is scheduled for July 22, 2026, with analyst consensus at 'buy' and a mean price target of ~$178.

The catalyst path

2026-10-28 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
IBI-10090	Phase 3	Inflammation

Price & technical context

3-month

-2.9%

6-month

+53.6%

12-month

+4.0%

52-wk range

$80.08–$202.92

vs 50-day MA

+1.4%

vs 200-day MA

+15.9%

Realized vol

73.5%

Max drawdown

-74.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for ICLR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.